Introduction
Over the past decade, RNA sequencing technology allowed to discover that the non-coding part of the genome represents around 1/5 of all transcript amount 1, 2 . These non-coding RNAs (ncRNA) are less conserved between species than protein coding genes, but more than introns and random intergenic regions 3, 4 . It is therefore likely that these non-coding transcripts have biological roles, which are being progressively deciphered, but still remain largely unknown. Around 30-50% of the protein coding gene loci are additionally expressing ncRNA in an opposite direction of the protein coding gene 4, 5 . These naturally occurring antisense transcripts, called NATs, have been less studied than the other classes of ncRNA for technical reasons because their detection and quantification require to preserve information about the transcript originating strand along the sequencing process. Indeed, standard RNA sequencing and expression micro-array techniques require double-stranded cDNA synthesis, which erases RNA strand information, leading to an expression quantification that is the sum of the expressions of the coding RNA and its corresponding NAT. Commercial kits allowing to gather this information have only been made available recently, paving the way to high-throughput studies of stranded RNA sequencing.
NAT expression is subjected to the same expression regulation than other genes, but NATs accumulate preferentially into the nucleus -associated to chromatin -unlike coding mRNAs which are located into the cytoplasm. NATs are also found in other cellular compartments such as mitochondria 6, 7 . NAT expression is described in many punctual examples to affect the activity of their sense or neighboring genes in biological events like cell differentiation and carcinogenesis, distinct molecular mechanisms being involved [8] [9] [10] [11] . NATs can regulate gene expression in trans or in cis. Given the fact that both the sense and antisense transcripts are transcribed from the same genomic region, it is expected that antisense transcripts behave more frequently in cis than other ncRNAs that commonly function in trans 11 .This last feature means that NATs may regulate their protein coding gene counterpart at the same locus, which is of great interest from the therapeutic point of view: NATs may thus provide a unique entry point for therapeutic intervention on targeted genes by the use of ASO (antisense oligonucleotides) that are drugs already FDA-approved for several diseases 8, [12] [13] [14] .   5 To date, a few studies have been performed at the whole transcriptome scale to investigate the role of NATs in the context of breast cancers. These studies have demonstrated that pairs of NAT/PCT are globally deregulated in this pathology [15] [16] [17] . However, none of those studies compared the whole transcriptome of paired tumorous and healthy tissues of the same patients, with a technology that keeps the strand information of the transcripts. Yet, such an experimental design would be needed to explore if NAT tumor deregulations are cancer-specific, in order to define if they could play a role in the pathology. Here, we describe the results of such an experimental design, in a cohort of 22 ER+ breast cancer patients whose paired healthy and tumorous tissues were analyzed by stranded RNA sequencing.
This work allows clarifying the role played by NATs to regulate their protein coding gene counterpart on the same locus in the breast cancer pathology and to quantify to what extent this phenomenon is occurring. We first defined 3 lists of NAT/PCT pairs that are both deregulated between healthy/tumorous tissues and related to NAT-specific regulations. Next, we demonstrated that those lists are enriched with survival-associated genes. Finally, we established a list of breast cancer-related genes probably regulated by their NATs that could be targeted by ASO in a therapeutic objective.
Results
The role played by NATs on the expression regulation of their corresponding coding transcripts is still largely unknown, as well as if this potential regulation could play a role in the ER+ breast cancer pathology. Our study experimental design used to answer this question at the whole genome scale is depicted in Figure 1 . Twenty-two tumorous tissues of ER+ breast cancer patients, as well as their paired adjacent healthy tissues, were subjected to strand-specific RNA Sequencing and DNA copy number analysis by CGH array. The patient characteristics are summarized in Table 1 . The cohort contains only tumors larger than 20mm, and is equally divided between luminal A and B sub-types, and between highly (Ki67>19%) and moderately (Ki67<19%) proliferating tumors. Most of them present a Bloom grade of 2 and 3.
RNA-Seq Validation
The combined analysis of the DNA copy number variations and modifications of RNA transcripts expression levels between tumor and healthy tissues validates our RNA-Seq analysis: the overall expression levels of coding gene transcripts inside genomic amplification or deletion newly acquired in the tumor were respectively increased and decreased, as expected (Figure 2 A) .
Moreover, the gene expression changes between healthy and tumor tissues obtained in our RNA-Seq dataset were compared with those obtained in an independent dataset (GSE65216). Gene expression variations between 10 mammary healthy tissues and 22 ER+ tumors (11 luminal A and 11 luminal B) were extracted using Geo2R 18 . The expression fold-change of genes that were found to be differentially expressed with an adjusted p-value <0.05 between healthy and tumoral tissues in both our and the GSE65216 datasets were compared, and present an average Spearman correlation coefficient of 0.613 (p-value<0.001). Moreover, 76.6% of those genes were differentially modulated in the same direction (Figure 2 B) . At a smaller scale, some RT-qPCR experiments were performed on the RNA samples that were used for our RNA-Seq study to confirm variations of several transcripts expression between tumor and healthy tissues. Among others, the downregulation in tumors of the ADAMTS9 tumor suppressor and its NAT, ADAMTS9-AS2, were confirmed by RT-qPCR (Figure 2 C).
NAT expression accounts for 17% of their coding counterpart in healthy tissues and increases to 26% in tumors.
We next defined the pairs of protein-coding genes and their corresponding antisenses as detailed in the material and methods section. This list can be found in Supplementary Table and contains 9632 NAT/PCT pairs where at least one patient has a non-null expression for PC or AS, either in normal tissue or in tumor. As 19846 coding transcripts were expressed in mammary tissues, 49% of coding transcripts have a concomitant corresponding NAT expression. Globally, NAT read counts represent 17% of their coding counterparts in healthy tissues and 26% in tumors ( Table 2 ), suggesting a global increase of the expression levels of NATs in mammary tumors. Moreover, the average read counts ratio between PCT/NAT gene pairs expressed simultaneously by a locus is 1544 in healthy tissues and 1013 in tumors ( Supplementary Table) .
Unexpectedly, we observe that the fold change distributions of NATs present both in genomic amplifications and deletions are shifted towards higher fold-changes than the corresponding distributions based on protein-coding genes (Figure 3 A) .
Based on the levels of expression in the different tissue types, we chose to focus on NAT/PCT pairs where both the PC and the AS were expressed in at least 7 out of the 22 patients, both in the tumor and the healthy tissue. This represents more than 60% of the total read counts of NAT/PCT pairs ( Table 2 ). In this group of 4884 genes pairs, NAT expression is greatly increased and accounts for 31% of their coding counterpart in healthy tissues and 47.8% in tumor. This gene sub-group contains PC genes that display the stronger potential of being regulated by their NAT counterparts.
Positive correlation of expression between NAT and their corresponding PCT are created in tumorous tissues.
In order to highlight newly appearing or disappearing correlations between NATs and their corresponding PCTs in the tumor, differential correlation analysis between all pairs of PCTs and NATs was performed with the DGCA software (v. 1.0.1) 19 . Complete results can be found in Supplementary   Table, Table 3 showing that genes that are well known in the breast cancer field are displaying deregulated correlation of expression with their antisense transcripts.
Protein coding genes exhibiting deregulated corresponding NAT expression in tumors are preferentially related to survival of breast cancer patients
Three different gene selection methods were used to extract NAT/PCT pairs potentially related to the breast cancer pathology out of the 4884 pairs. Firstly, the previously described DiffCor is based on the differential correlation of NAT/PCT read counts between healthy and tumors tissues. A list of NAT/PCT pairs whose correlation is significantly different between normal and tumor tissues (p-value < 0.05) and whose correlation class differs between tumor and normal tissues (ie. 0/0, +/+, -/-classes are removed) has been selected and contains 441 NAT/PCT pairs.
The second method is based on the differential expression of the NATs between tumors and healthy tissues. A list of 738 NAT/PCT pairs where the NATs were significantly differentially expressed (adjusted p-value < 0.05) between normal and tumor tissues has been determined.
The third method is based on the variation of the NAT/PCT ratio between healthy and tumor tissues, 
cancer genes present a deregulated profile of NAT expression in breast cancer samples.
When the Cancer Gene Census list of genes from the COSMIC database (http://cancer.sanger.ac.uk/census) was compared with the content of our 3 lists of genes that are probably regulated by their NATs and implicated in the breast cancer pathology, 72 genes were found in common (S13 - Supplementary Figures ). This list contains cancer genes that could be targeted by ASO, designed to interact with the corresponding NATs of those genes, in order to specifically regulate their expression.
Discussion
Breast cancer constitutes a public health problem: around 1out of 8 women will suffer from it during their lifetime in industrialized countries. The most frequent subtype is the estrogen receptor expressing breast cancer (ER+/HER2-), with 75% of occurrences. In case of primary disease, most patients are treated by surgery with or without radiotherapy and endocrine therapy. However, a large number of those cancers will suffer from a relapse and develop metastases -a major life-threatening event which is strongly associated with poor outcome -and require chemotherapy in case of symptomatic visceral disease. New therapies are thus searched as well as biomarkers that would give a better prediction of the risk of relapse. Our study explores the still new field of antisense transcription to define cancer gene lists, and will lead to further works to define predictive markers and/or tailor targeted treatment by antisense oligonucleotides (ASO) 14 .
This is the first time that a whole transcriptome strand-specific RNA-Seq study focusing on the antisense transcription is performed in paired tumor and healthy mammary tissues. This experimental design allows to detect deregulation of NAT expression that occurs in cancer tissues, and to statistically connect them with the changes of the corresponding coding transcript expression. In particular, we revealed that many positive correlations between NATs and their PCT counterpart were appearing or fading in the tumor, suggesting newly acquired or lost regulations of the protein-coding transcripts in the cancerous tissues. Further functional molecular studies will however be needed to confirm the existence of such regulations of the PCTs by their NATs in the list of cancer gene pairs that were highlighted in this work.
The difference in fold-change between NATs located in genomic alterations and their coding counterparts, with NATs showing higher fold-changes, as well as the significant increase in NAT expression in tumors tend to indicate that NATs may be subject to a particular activating mechanism specific to tumors (Figure 3 A, Table 2 ).
Moreover, the association of these NATs with survival, which was evaluated through the use of their protein-coding counterparts as proxy in a large independent cohort, shows that the dysregulation observed within the landscape of NATs is not merely a random byproduct of the tumoral process.
Analyses were conducted to explore the relationship of the PC and AS genes with known prognostic factors, but no significant results were found. In the same way, enrichment analyses in pathways genes were conducted without any noticeable results.
Several studies have already explored the role of antisense transcription in breast cancer [15] [16] [17] . the PCT is expressed around 1000 times more than the NAT, but we have additionally observed that this difference of expression is lower in tumors than in healthy tissues. We also measured that globally, 10% of the transcripts were coming from the antisense strand in healthy tissues and that this proportion is increased to 13% in tumors (8% were described by Balbin et al.) . However, some patients present a much higher increase of NAT/PCT proportion in the tumor than others. This heterogeneity in NAT expression deregulation across patients could be used to stratify patients into subgroups of different prognosis. One limitation of our study is the small size and the short follow-up time of our cohort, which did not allow performing such type of analysis.
Our results also confirm the observation by Grinchuk et al that the expression correlations between NAT and PCT were different in tumors when compared to unrelated healthy tissues. We refined this 12 observation by using paired tissues of the same patient, and showed that globally these correlations become more significant and more positive in the tumors. Moreover, we highlighted the gene pairs where potential new PCT/NAT expression regulation occurs in cancerous tissues. After having performed a survival analysis with gene expression data from an external cohort (TCGA), it appears that these NAT/PCT gene pairs were also enriched in survival-associated genes, suggesting that the opposite strand transcription regulation might play a role in the breast cancer disease. Therefore, our report opens a new field of investigation in cancer and indicates that NAT expression is often increased in cancer samples as compared to matched normal tissues. The relevance of this observation for coding gene expression, cancer biology, prognosis and treatment will need to be determined in specific and large cohorts of paired samples.
Material and Methods

Ethical Statement
Tissues were obtained from the Liege University Biobank (N=12) and from the St Vincent Clinic of Rocourt (N=11), Belgium. This study was approved by the local institutional ethical board (2010/229).
All aspects of the study comply with the Declaration of Helsinki. Patients of the Liege University
Hospital were recruited on the basis of an opt-out methodology. Patients of the St Vincent Clinic of Rocourt were informed of the research work and provided written informed consent.
Patients and samples
This retrospective study was performed on 23 cryopreserved cancerous and adjacent healthy tissues from 23 women suffering from estrogen receptor expressing breast cancer. Samples were collected from 2010 to 2014. One patient was excluded because of poor strand-specificity of the RNA-Seq. The clinical and pathological parameters of the patients included in the final analysis were recorded and summarized in Table 1 .
A summary of the experimental design is depicted in Figure 1 .
DNA/RNA/miRNA extraction
DNA, RNA and miRNA were simultaneously extracted using All Prep DNA/RNA/miRNA Universal kit (Qiagen, Belgium) according to the manufacturer protocol. The RNA quality was assessed using a BioAnalyzer (Agilent, Belgium). Detection Methods 2 algorithm (ADM-2 ) was used with a cut-off 6.0, followed by a filter to select regions with three or more adjacent probes and a minimum average log2 ratio ± 0.25, was used to detect copy number changes. The quality of each experiment was assessed by the measurement of the derivative log ratio spread with CytoGenomics software v2.0. Genomic positions were based on the UCSC February 2009 human reference sequence (hg19) (NCBI build 37 reference sequence assembly). Filtering of copy number changes was carried out using the BENCHlab CNV software (Cartagenia, Leuven, Belgium). 
Gene expression quantification by RNA-Sequencing
Quantitative RT-qPCR
Reverse transcription was performed using the Reverse Aid H Minus kit (LifeTechnologies, Belgium) from 100 ng of total RNA using random hexamer primers in case of coding genes and using a target specific primers coupled to an unrelated synthetic DNA oligonucleotide in case of NAT.
Quantitative PCR were performed using specific 6-FAM/ZEN/IBFQ probes (IDT, Belgium) with Kapa Probe Fast qPCR Master Mix (Sopachem, Belgium) on a LightCycler 480 apparatus (Roche). In case of coding gene amplification, the primers were designed according to standard procedure. In case of NAT gene amplification, a primer specific to the target NAT and a primer specific to the synthetic oligonucleotide added during the reverse transcription are used to allow a stand-specific amplification.
The relative expression was calculated using the standard curves methods, using β2microglobuline as endogenous standard.
Gene expression variations were retrieved from de GEO Dataset GSE65216 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65216), which is an expression study by micro-array (Affymetrix) of the Maire's breast cancer cohort 23 .
Definition of the protein-coding/antisense pairs
The list of pairs of protein-coding genes and their corresponding antisense has been generated based on the human genome assembly and gene annotation GRCh37 (release 75) from Ensembl 24 . To be included in the list, pairs of genes have to fulfill the 3 following conditions: overlapping coordinates; opposite strands; one of the two genes has to have the protein_coding biotype, while the other can have any of the following biotypes: 3prime_overlapping_ncrna, antisense, IG_C_pseudogene, IG_V_pseudogene, lincRNA, misc_RNA, polymorphic_pseudogene, processed_transcript, pseudogene, sense_intronic, sense_overlapping, snoRNA, snRNA. The reasoning behind including all non-protein_coding biotypes as putative antisenses is that the Ensembl annotation of antisenses is limited to already validated antisenses, and it might thus miss out previously unknown antisenses.
NAT/PCT Gene list selection methods
1) DiffCor list: Differential correlation analysis between pairs of protein-coding and antisense
transcripts was performed with the DGCA software (v. 1.0.1) 19 . Pairs of protein coding/antisense genes whose correlation is significantly different between normal and tumor samples (adjusted p-value < 0.05) and whose correlation class differs between tumor and normal samples (ie. we removed the 0/0, +/+, -/-classes) have been selected. For all three gene list selection methods, pairs of genes where either the protein-coding or the antisense was expressed in less than 7 tumor samples or 7 healthy samples have been discarded.
2) NATDiffExp list: Differential expression analysis between all tumor and healthy samples was
Survival analysis
All protein-coding genes of the 3 gene lists have been tested for association with survival on an external dataset of 1066 RNA-Seq samples from the tumors of female breast cancer patients (Package R TCGA Biolinks; 25 ). Association with survival was recorded when the p-value of a log-rank test was inferior to 0.05. The ratio of genes associated with survival in each list has been compared with the same ratio computed with a list of randomly selected protein-coding genes. This study was focused on NAT/PCT pairs where both the PCT and the AS were expressed in at least 7 out of the 22 patients, both in the tumor and the healthy tissue. This group of 4884 gene pairs contains 60% of the total reads counts, and the NAT/PCT ratio expression is increased in tumors. RNA and DNA were simultaneously extracted from 23 breast cancer ER+/HER2-tumors and their paired adjacent healthy tissues. Strand-specific paired-end RNA sequencing and comparative genomic hybridization (CGH) were performed. Quality control steps and RNA-Seq validation were performed and lead to the elimination of one patient because of a poor strand specificity of this sample. This strategy allowed to study differential expression of NATs and PCTs between tumors and healthy tissues, and to perform differential correlation analysis of NAT/PCT pairs. Three lists of genes with deregulated NAT expression in the tumors that could potentially affect their corresponding PC expression were extracted, and the coding genes they contain were subjected to survival analysis with an external cohort (TCGA). 
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